Veterinary Vaccines Market to 2017 - Europe to Strengthen Its Position as the Single Largest Market for Animal Vaccines Due To Highly Organized Livestock Farms
GBI Research analyzes the veterinary vaccines market up to 2017. The report examines the market by analyzing livestock species including bovine, ovine, equine and porcine. The target population considered is the total animal population in each respective region. The report specifically covers livestock species excluding companion animals, and concludes that the livestock market sector has shown steady growth in recent years. Biotechnology developments and research contributed tremendously towards the growth and enhancement of the veterinary vaccines market. Europe and the US collectively hold more than 70% of the total market.
The market grew at a steady rate for the past few years and is expected to grow further. The demand for veterinary vaccines in the market is driven by factors such as the vulnerability of animals to fatal and chronic diseases, and the changing patterns of the diseases. The recent epidemics created awareness among livestock owners of the need to avoid the huge production losses due to diseases such as swine flu, avian influenza and anthrax. The future of vaccines will be dominated by DNA-related vaccines and combination vaccines, which can provide protection against various diseases with minimal vaccine shots. Such innovative products will be more capable of providing protection and generating a strong immune response than the traditional vaccines.
The key players in the veterinary vaccines market are Bayer HealthCare, Merck & Co. Inc., Fort Dodge Animal Health, Novartis Animal Heath, Pfizer, Lohmann Animal Health, Merial Ltd., Boehringer Ingelheim GmbH, and Heska Corporation. There are many other companies which are involved with the manufacturing and development of veterinary vaccines apart from those in the list.
Scope
Annualized market data for the veterinary vaccines market from 2002 to 2010, forecast forward to 2017.
Analysis of the leading livestock segments, including bovine, ovine, porcine and equine.
Analysis of the veterinary vaccines market in the leading geographies of the world, which include the US, Europe and Japan.
Market characterization of the veterinary vaccines market, including market size, annual cost of vaccination and target population.
Key drivers and barriers that have a significant impact on the market.
Competitive benchmarking of leading companies. The key companies studied in this report are Bayer, Pfizer, Merck and Novartis.
Key M&A activities and licensing agreements that have taken place in the veterinary vaccines market.
Reasons to buy
Align your product portfolio to the markets with high growth potential.
Develop market-entry and market expansion strategies by identifying the leading livestock segments and geographic markets poised for strong growth.
Develop key strategic initiatives by understanding the key focus areas of leading companies and niche companies which are helpful in extending the pipeline portfolio.
Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
Executive Summary
GBI Research, the leading business intelligence provider, has released its latest research, “Veterinary Vaccines Market to 2017 - Europe to Strengthen Its Position as the Single Largest Market for Animal Vaccines Due To Highly Organized Livestock Farms”. The report analyzes the markets for veterinary vaccines, covering bovine, ovine, porcine and equine species in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), and Japan. The report also provides geographical landscape, competitive landscape, product profiles, and analysis of drivers and barriers that impact the veterinary vaccines market. Furthermore, the report provides company profiling, SWOT analysis for the leading companies, and analysis of the mergers, acquisitions, recent activities and licensing agreements that shape the global markets.
The veterinary vaccines market has shown growth over recent years, which can be attributed to good animal husbandry practices and better management of farms. This results in the estimation of further growth in the market due to the advancement in biotechnological research and the tremendous development in the innovation of new vaccines for various diseases.
The Global Veterinary Vaccines Market Will Witness Consistent Growth with Europe to Continue to Dominate
The global veterinary vaccines market grew at the rate of 1% from 2002-2010, and is likely to witness the same growth for the period 2011-2017. The European veterinary vaccines market grew at a CAGR of 1% from 2002 to 2010. The total livestock vaccines market was estimated to be worth $2.9 billion in 2010, and is expected to grow at the same rate to reach $3.1 billion in 2017.
As per the GBI Research analysis, Europe is expected to hold a major share in the veterinary vaccines market by 2017, with $3.1 billion in revenues, whereas the US market is estimated to reach $2.9 billion, contributing 48% to the total veterinary vaccines market.
The Bovine Vaccines Market is the Largest Market Due to the Organized Dairy and Beef Producing Sectors
The bovine vaccines market is the largest livestock vaccines market. In 2017, the market size for bovine vaccines is estimated to be $3 billion, out of which the US contributes $1.6 billion, Europe $1.3 billion, and Japan $70.4m. The market is expected to grow at the rate of 0.7% in the US and Europe.
The dairy and beef sectors are being converted into organized sectors in the developed countries, and a proper vaccination schedule is being followed. This is one of the main reasons for the growth in the bovine vaccines market.
The annual cost of vaccination (ACV) in the US was $12.9 for a cow-calf unit in 2002, and grew at a rate of 2.4% to reach $15.6 per cow-calf unit in 2010. A cow-calf unit refers to a unit which includes a cow with one or two calves. The ACV is estimated to grow from $15.6 to $17.6, at a CAGR of 2% for a cow-calf unit for the forecast period between 2010 and 2017.
The Ovine Vaccines Market is One of the Fastest Growing Veterinary Vaccines Markets in the US, With an Estimated Growth Rate of 4% between 2010 and 2017
The sheep vaccines market in the US grew at the rate of 13.7% from 2002 to 2010. The market was estimated at $22.1m in 2010, and is expected to grow at the rate of 4% from 2010 to 2017. The estimated market size in 2017 is $29.2m. This market is estimated to grow at the fastest rate (4%) among all the livestock vaccines markets. The sheep population in the US grew at a rate of 3% from 2002 to 2010. The total sheep population in the US was estimated at 3.2 million for 2010. The population is estimated to be 3.9 million by 2017. The population is expected to grow with the same rate for the next seven years.
Table of Contents
Table of Contents
1. Table of Contents
1.1. List of Tables
1.2. List of Figures
2. Introduction
2.1. GBI Research Report Guidance
3. Veterinary Vaccines Market to 2017 - Market Overview
3.1. Revenue Forecasts
3.2. Drivers
3.2.1. Livestock Owners Developing Increased Disease Awareness for Farm Animals
3.3. Barriers
3.3.1. Mutant Strains of Virus Pose a Challenge in Vaccine Manufacturing
3.3.2. Decrease in Cattle Population is Reducing the Demand for Vaccines
4. Veterinary Vaccines Market to 2017 - Geographical Landscape
4.1. The US
4.1.1. Revenue Forecast
4.2. Europe
4.2.1. Revenue Forecast
4.3. Japan
4.3.1. Revenue Forecast
5. Veterinary Vaccines Market to 2017 - Bovine Vaccines Market
5.1. The US
5.1.1. Revenue Forecasts
5.1.2. Annual Cost of Vaccination
5.1.3. Target Population
5.2. Europe
5.2.1. Revenue Forecasts
5.2.2. Annual Cost of Vaccination
5.2.3. Target Population
5.3. Japan
5.3.1. Revenue Forecasts
5.3.2. Annual Cost of Vaccination
5.3.3. Target Population
6. Veterinary Vaccines Market to 2017 - Ovine Vaccines Market
6.1. The US (Sheep Vaccines Market)
6.1.1. Revenue Forecasts
6.1.2. Annual Cost of Vaccination
6.1.3. Target Population
6.2. Europe (Sheep Vaccine Market)
6.2.1. Revenue Forecasts
6.2.2. Annual Cost of Vaccination
6.2.3. Target Population
6.3. Japan (Sheep Vaccines Market)
6.3.1. Revenue Forecasts
6.3.2. Annual Cost of Vaccination
6.3.3. Target Population
6.4. The US (Goat Vaccines Market)
6.4.1. Revenue Forecasts
6.4.2. Annual Cost of Vaccination
6.4.3. Target Population
6.5. Europe (Goat Vaccines Market)
6.5.1. Revenue Forecasts
6.5.2. Annual Cost of Vaccination
6.5.3. Target Population
6.6. Japan (Goat Vaccines Market)
6.6.1. Revenue Forecasts
6.6.2. Annual Cost of Vaccination
6.6.3. Target Population
7. Veterinary Vaccines Market to 2017 - Porcine Vaccines Market
7.1. The US
7.1.1. Revenue Forecasts
7.1.2. Annual Cost of Vaccination
7.1.3. Target Population
7.2. Europe
7.2.1. Revenue Forecasts
7.2.2. Annual Cost of Vaccination
7.2.3. Target Population
7.3. Japan
7.3.1. Revenue Forecasts
7.3.2. Annual Cost of Vaccination
7.3.3. Target Population
8. Veterinary Vaccines Market to 2017 - Equine Vaccines Market
8.1. The US
8.1.1. Revenue Forecasts
8.1.2. Annual Cost of Vaccination
8.1.3. Target Population
8.2. Europe
8.2.1. Revenue Forecasts
8.2.2. Annual Cost of Vaccination
8.2.3. Target Population
8.3. Japan
8.3.1. Revenue Forecasts
8.3.2. Annual Cost of Vaccination
8.3.3. Target Population
9. Veterinary Vaccines Market to 2017 - Competitive Landscape
9.1. Company Profiles
9.1.1. Bayer HealthCare
9.1.2. Pfizer
9.1.3. Merck Inc.
9.1.4. Novartis
10. Veterinary Vaccines Market to 2017 - Product Profiles
10.1. Bovine Vaccines
10.1.1. Alpha-7
10.1.2. Vira Shield 6 + VL5
10.1.3. Salmonella Newport Bacterial Extract SRP
10.1.4. Imrab Large Animal
10.1.5. Anthrax Spore Vaccine
10.1.6. J-5 E. Coli Bacterin
10.2. Ovine Vaccines
10.2.1. Ultrabac 7
10.2.2. Ultrabac CD
10.2.3. Clostri Shield 7
10.3. Porcine Vaccines
10.3.1. Parvo Shield L5E
10.3.2. Porcine Pili Shield+C
10.3.3. LitterGuard LT-C
10.3.4. Farrowsure Gold B
10.4. Equine Vaccines
10.4.1. Recombitek Equine West Nile Virus Vaccine
10.4.2. Fluvac Innovator 6
10.4.3. Prestige V + VEE
10.4.4. Potomavac
10.4.5. Imrab 3
11. Veterinary Vaccines Market to 2017 - Mergers & Acquisitions
11.1. Phibro Animal Health Completed Acquisition of Abic Animal Health in February 2009
11.2. Ceva Acquired Vetech Laboratories in October 2011
11.3. Ceva Acquired CentaurVA Animal Health in October 2011
11.4. Harbin Pharma Acquired Pfizer's Swine Vaccine Business in June 2010
11.5. Boehringer Ingelheim Animal Health Acquires a Significant Portion of the Fort Dodge Animal Health Business from Pfizer in October 2009
11.6. Pfizer Acquired Microtek International in May 2010
11.7. Virbac Acquired Certain Veterinary Products from Pfizer in February 2010
12. Veterinary Vaccines Market to 2017 - Licensing Agreements
12.1. Heska Corporation Amends Bovine Vaccine Agreement with AgriLabs
12.2. Pfizer Animal Health Inks Global Licensing Deal with Epitopix
12.3. GenVec Enters into Collaboration with Merial to Develop and Commercialize FMD Vaccine
12.4. Vical Enters into Agreement with Japanese Partner for Veterinary Pandemic Influenza Vaccine
13. Veterinary Vaccines Market to 2017 - Recent Activities
13.1. Intervet's Equine West Nile Vaccine Approved by USDA (United States Department of Agriculture)
13.2. Defra Launched Bovine Tuberculosis Vaccine
13.3. Boehringer Ingelheim Vetmedica Receives Approval for Express FP and Express Vaccines from the USDA
Veterinary Vaccines Market to 2017 - Europe to Strengthen Its Position as the Single Largest Market for Animal Vaccines Due To Highly Organized Livestock Farms published by GBI Research in January 16, 2012. This report consists of Pages: 76 and the price starts from US $ 3500.
